These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27443782)

  • 1. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.
    Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M
    Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis.
    Nguyen LBL; Lemoine M; Ndow G; Ward ZJ; Hallet TB; D'Alessandro U; Thursz M; Nayagam S; Shimakawa Y
    Lancet Glob Health; 2024 Jan; 12(1):e66-e78. PubMed ID: 38097300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study.
    Lemoine M; Shimakawa Y; Njie R; Taal M; Ndow G; Chemin I; Ghosh S; Njai HF; Jeng A; Sow A; Toure-Kane C; Mboup S; Suso P; Tamba S; Jatta A; Sarr L; Kambi A; Stanger W; Nayagam S; Howell J; Mpabanzi L; Nyan O; Corrah T; Whittle H; Taylor-Robinson SD; D'Alessandro U; Mendy M; Thursz MR;
    Lancet Glob Health; 2016 Aug; 4(8):e559-67. PubMed ID: 27443781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
    Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa.
    Mokaya J; Burn EAO; Tamandjou CR; Goedhals D; Barnes EJ; Andersson M; Pinedo-Villanueva R; Matthews PC
    BMC Public Health; 2019 Jun; 19(1):829. PubMed ID: 31242901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study.
    Nayagam S; de Villiers MJ; Shimakawa Y; Lemoine M; Thursz MR; Walsh N; Hallett TB
    Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):635-645. PubMed ID: 37150181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
    Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
    Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
    Yuan Y; Iloeje UH; Hay J; Saab S
    J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of different monitoring strategies in a screening and treatment programme for hepatitis B in The Gambia.
    Schmit N; Nayagam S; Lemoine M; Ndow G; Shimakawa Y; Thursz MR; Hallett TB
    J Glob Health; 2023 Jan; 13():04004. PubMed ID: 36655869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
    Tamandjou Tchuem CR; Andersson MI; Wiysonge CS; Mufenda J; Preiser W; Cleary S
    Vaccine; 2021 May; 39(23):3141-3151. PubMed ID: 33962836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load.
    Fan L; Owusu-Edusei K; Schillie SF; Murphy TV
    Obstet Gynecol; 2014 May; 123(5):929-937. PubMed ID: 24785842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030.
    Xiao Y; Hellard ME; Thompson AJ; Seaman C; Howell J; Scott N
    Med J Aust; 2023 Mar; 218(4):168-173. PubMed ID: 36596568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of screening immigrants for hepatitis B.
    Wong WW; Woo G; Jenny Heathcote E; Krahn M
    Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.
    Wong WW; Hicks LK; Tu HA; Pritchard KI; Krahn MD; Feld JJ; Chan KK
    Breast Cancer Res Treat; 2015 Jun; 151(3):639-52. PubMed ID: 25962692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of hepatitis B screening economic evaluations in low- and middle-income countries.
    Wright CM; Boudarène L; Ha NT; Wu O; Hawkins N
    BMC Public Health; 2018 Mar; 18(1):373. PubMed ID: 29558894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of couple-based immunization strategy to prevent mother-to-child transmission of hepatitis B virus in China: A decision-analytic Markov model.
    Jing W; Liu J; Wu Y; Ma Q; Liu M
    EClinicalMedicine; 2020 Feb; 19():100264. PubMed ID: 32055793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
    Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
    Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of active-passive prophylaxis and antiviral prophylaxis during pregnancy to prevent perinatal hepatitis B virus infection.
    Fan L; Owusu-Edusei K; Schillie SF; Murphy TV
    Hepatology; 2016 May; 63(5):1471-80. PubMed ID: 26509655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.